|
Daily Medical Update
Polycystic ovary syndrome
Tuesday, October 06, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Human reproduction update (2026) - Systematic Review
Key Findings
- Across 92 pooled studies including 157,181 participants, adult PCOS prevalence was 12.1% by Rotterdam criteria, 7.9% by NIH criteria, 12.7% by AE-PCOS criteria, and 7.8% by self-report.
- Using Rotterdam criteria, prevalence was highest in the Eastern Mediterranean region (15.1%) and South-East Asian region (14.3%), followed by Europe (11.7%), the Americas (10.5%), and the Western Pacific (9.1%); no African data were available.
📋 Practice Implication: Use the diagnostic criteria and geographic context when estimating PCOS burden and planning screening, because substantial heterogeneity and low-certainty evidence limit application of a single prevalence estimate to every population.
|
Frontiers in endocrinology (2026) - Systematic Review
Key Findings
- In 22 studies of 5,507 women with PCOS, pooled gestational diabetes prevalence was 24% (95% CI 20%-28%), with a 10%-46% prediction interval and substantial heterogeneity; cohort studies estimated 21.7%.
- Increased odds of gestational diabetes were associated with pre-pregnancy BMI (OR 1.39), gestational weight gain (OR 1.58), HOMA-IR (OR 3.41), and a family history of diabetes (OR 2.88).
📋 Practice Implication: Treat pregnancy in women with PCOS as a high-risk setting for gestational diabetes and front-load glucose and weight surveillance, while recognizing that the reported risk factors are observational associations rather than tested interventions.
|
European journal of endocrinology (2026) - Systematic Review
Key Findings
- Across 11 randomized controlled trials, add-on GLP-1 receptor agonists reduced BMI versus control by 1.38 kg/m2 (95% CI -2.39 to -0.38), but the certainty of evidence was low.
- No reduction was observed in LDL cholesterol or triglycerides, and evidence was insufficient for glucose, insulin, hirsutism, or menstrual regularity; no studies assessed quality of life, mental health, or cost-effectiveness.
📋 Practice Implication: Position GLP-1 receptor agonists primarily as a short-term weight-management option in PCOS and avoid assuming reproductive, psychological, or broad metabolic benefits until higher-certainty evidence is available.
|
Frontiers in endocrinology (2026) - Network Meta-Analysis
Key Findings
- GLP-1 receptor agonist plus metformin produced the largest reductions in weight (mean difference -5.58 kg; 95% CI -8.57 to -2.59) and BMI (mean difference -2.17; 95% CI -2.77 to -1.58).
- GLP-1 monotherapy also reduced weight by 5.22 kg and BMI by 2.00, and reduced waist circumference by 4.70 cm; no intervention significantly improved HOMA-IR, and results were heterogeneous.
📋 Practice Implication: For patients prioritizing anthropometric change, GLP-1-based therapy—particularly combined with metformin—may be considered through shared decision-making, but the lack of HOMA-IR benefit and unassessed reproductive outcomes limits claims of overall superiority.
|
Journal of ovarian research (2026) - Network Meta-Analysis
Key Findings
- Among 29 randomized controlled trials involving 1,771 participants, SGLT-2 inhibitors had the largest reductions in BMI (mean difference -4.26 kg/m2; 95% CI -6.01 to -2.52) and HOMA-IR (-2.56; 95% CI -4.53 to -0.59) versus placebo.
- Metformin plus GLP-1 receptor agonists produced the largest reductions in total testosterone (-1.35 ng/mL; 95% CI -2.22 to -0.48) and free androgen index (-1.91; 95% CI -3.43 to -0.40), while GLP-1 monotherapy had the greatest nausea, vomiting, and abdominal-pain risk and metformin/DPP-4 inhibitor regimens markedly increased diarrhea.
📋 Practice Implication: Match the agent to the treatment target—SGLT-2 inhibition for weight and insulin resistance versus metformin-GLP-1 combinations for hyperandrogenism—while counseling about gastrointestinal intolerance and the low certainty of many comparisons.
|
|
💡
Summary
Recent evidence frames polycystic ovary syndrome as common and heterogeneous, with global adult prevalence around 12.1% by Rotterdam criteria and elevated gestational diabetes risk during pregnancy. Pharmacologic reviews support modest short-term weight benefit from GLP-1 receptor agonists, with greater anthropometric reductions reported for GLP-1 plus metformin, while novel antidiabetic agents show differing effects on weight, insulin resistance, and hyperandrogenism. Much of the evidence is low-certainty or heterogeneous, so treatment selection should remain phenotype- and outcome-specific.
|
|